Blood Plasma Market Shares, Market Strategies, and Market Forecasts, 2023 to 2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,800	330 Pages	WinterGreen Research	January, 2023	WGR17631863

Best Price Guarantee
Price	from $4,800
Length	330 Pages
Publisher	WinterGreen Research
Published Date	January, 2023
SKU	WGR17631863

Blood Plasma Market Shares, Market Strategies, and Market Forecasts, 2023 to 2029

Blood is the essence of life. Blood plasma provides significant health benefits. The varieties of proteins and other components of blood are in demand worldwide. Blood proves its value by treating disease. Worldwide markets are poised to achieve continuing growth as human blood is further fractionated to address more disease treatments and becomes more effective in the research and development aspects of medical care delivery.

1. Serum (Blood): Market Description and Market Dynamics: 1.1 Blood Plasma; 1.1.1 Plasma Carrier For Nutrients, Hormones, Proteins; 1.1.2 Immunotherapy Plus Chemotherapy; 1.2 Liver Disease Is A Major Cause Of Illness And Death In China; 1.2.1 Fractionation Technique for Manufacture Blood Products from Plasma: Treatment for Chronic Hepatitis B Infection; 1.3 Plasma Products Market Trends
2. Chinese Serum (Blood) Market Shares and Forecasts: 2.1 Chinese Serum (Blood) Market Driving Forces; 2.2 Serum (Blood) Market Shares; 2.2.1 Blood Serum Providers To China, Market Shares,; 2.2.2 Blood Company Descriptions; 2.2.3 Blood Company Descriptions; 2.2.4 Intense Competition Comes From Local And Overseas Pharmaceutical Enterprises in China; 2.2.5 30 Approved Manufacturers Of Plasma Products in China; 2.2.6 Major Competitors in China; 2.3 Serum (Blood) Market Forecasts; 2.3.1 Blood Market Segments; 2.3.2 Transpacific Trade In Human Blood Plasma Products; 2.3.3 Tons of Blood Plasma; 2.4 Serum (Blood) Market Segment Forecasts; 2.4.1 IgG; 2.4.2 Plasma Proteins Market; 2.4.3 Plasma Proteins Chinese Market; 2.4.4 Hep B Treatments; 2.4.5 Bovine Serum; 2.4.6 Applications For Processed Bovine Serum; 2.4.7 FBS; 2.4.8 FBS Cell Culture Process Of Growing Cells Under Controlled Conditions In Vitro; 2.4.9 ABS; 2.4.10 Newborn Calf Serum NBCS; 2.4.11 BCS; 2.4.12 Porcine Sera; 2.4.13 Biotechnology Industry; 2.4.14 Research Institutes; 2.4.15 Pharmaceutical; 2.4.16 Cosmetic Serums; 2.5 Global Animal Health Market; 2.6 Serum (Blood) Prices; 2.6.1 Corning Bolvine Serum; 2.6.2 Millipore / Sigma Aldrich Fetal Bovine Serum, FBS, FCS, Sera,; 2.6.3 Prices of Pharmaceutical Plasma Products; 2.7 Serum (Blood) Regional Market; 2.7.1 US; 2.7.2 Europe; 2.7.3 Australia; 2.7.4 China; 2.8 China Market For Cord Blood Banking; 2.9 Reimbursement in China; 2.9.1 Company Geographical Revenue
3. Serum (Blood) Product Description: 3.1 Plasma Source of Life; 3.1.1 Antithrombin III; 3.1.2 Protein C; 3.1.3 Fibrogammin; 3.1.4 Factor XI and factor XIII; 3.1.5 C1 esterase inhibitor
4. Blood Research and Technology: 4.1 Treatment for Chronic Hepatitis B Infection; 4.2 Plasma the Major Component Of Blood; 4.3 Genetically Engineered Blood Products; 4.4 Government Regulation; 4.2.1 United States Government Regulation; 4.3 European Government Regulation; 4.3.1 Each European Union member state has its own procedures for the authorization, within its own territory, of medicines; 4.4 Cord Blood; 4.5 Chinese Biological Product Regulations; 4.6 Chinese Drug Industry Under Attack
5 Serum (Blood) Company Profiles: 5.2 Blood Product Industry; 5.3 ANZCO Foods / Bovogen Biologicals; 5.3.1 Clients and Suppliers; 5.3.2 Development and Prospects; 5.3.3 ANZCO Foods Jointly Owned by Itoham Foods (Mitsubishi Corporation shareholder), Nippon Suisan Kaisha; 5.3.4 ANZCO Foods Animal Serum Product Sub-Lots; 5.3.5 ANZCO Foods / Bovogen Biologicals; 5.3.6 Bovogen Biologicals; 5.3.7 ANZCO Foods Revenue; 5.4 Ausgenex Pty Ltd; 5.4.1 AusGeneX Revenue; 5.5 Avantor; 5.5.1 Avantor / VWR Sole Supplier For Cell And Gene Therapy to Catapult.; 5.5.2 Avantor / VWR; 5.5.3 VWR Animal and Human Blood for Use in DNA/RNA Isolation or for Testing Infectious Diseases; 5.5.4 VWR; 5.5.5 Avantor Revenue; 5.5.6 VWR Revenue; 5.5.7 VMR Plasma-Based Biopharmaceutical Manufacturing Industry in China i; 5.5.8 VWR Suppliers; 5.6 Biochrom GmbH; 5.7 Biotest AG; 5.8 Cellsera Rutherford; 5.8.1 Cellsera Rutherford Certificates and Accreditations; 5.8.2 Cellsera Privately owned, 100% Australian company; 5.8.3 Cellsera Manufacturing Facility; 5.9 Changchun SRbiological; 5.9.1 Zen Bio Human Serum & Animal-Free Growth Supplement; 5.9.2 Zen Bio Human Serum Technical Advantage Over Animal Serum; 5.9.3 Zen-Bio Animal Serum - Cell Culture; 5.10 China Biologic Products; 5.10.1 China Biologic Sales; 5.10.2 China Biologic Acquisition TianXinFu; 5.10.3 China Biologic Products Holdings, Revenue; 5.10.4 China Biologic Sales Volume Of Products by Segment; 5.10.5 China Biologic Research And Development Expenses; 5.10.6 China Biologic Products Holdings, Manufacturing Facilities; 5.10.7 China Biologic Products Holdings; 5.11 Chinese Plasma Market Acquisitions; 5.12 Corning Life Sciences; 5.12.1 Corning Life Sciences Operation; 5.12.2 Corning Life Sciences Revenue Structure; 5.12.3 R&D and Investment; 5.12.4 Corning Life Sciences Sera Products; 5.12.5 Corning Cell Growth and Differentiation; 5.12.6 Corning Cancer Research; 5.12.7 Corning Cell Culture; 5.12.8 Custom Media and Sterile Solutions; 5.12.9 Corning® Fetal Bovine Serum; 5.12.10 Products; 5.12.11 Corning Regional Presence; CHINA; 5.13 Global Cord Blood Corp.; 5.14 CSL; 5.14.1 CSL 35 Per Cent Annual Growth in Chinese Albumin Sales; 5.14.2 CSL Bought 80 Per Cent Stake In Chinese Plasma Fractionator Wuhan Zhongyuan Ruide Biologics; 5.14.3 CSL addresses Market for 100 Million Chinese with Liver Problems; 5.15 ExCel Bio; 5.16 GE Healthcare Life Sciences; 5.16.1 GE HyClone™ Fetal Bovine Serum, Standard; 5.16.2 GE Healthcare HyClone™ AdvanceSTEM™ ES Qualified Amino Acids; 5.16.3 GE Healthcare HyClone™ Fetal Bovine Serum (Canada), Characterized; 5.16.4 GE Healthcare HyClone™ Fetal Bovine Serum, Super Low IgG; 5.16.5 GE Healthcare HyClone™ Fetal Bovine Serum, Human Mesenchymal Stem Cell Screened; 5.16.6 GE Healthcare HyClone™ Fetal Bovine Serum (New Zealand), Characterized; 5.16.7 GE Healthcare HyClone™ Fetal Bovine Serum, Defined; 5.16.8 GE Healthcare HyClone™ Fetal Bovine Serum, Characterized; 5.16.9 GE Healthcare HyClone™ Fetal Bovine Serum, Tetracycline Screened; 5.14.10 GE HyClone™ Bovine Growth Serum; 5.14.11 CBMG and GE Healthcare Life Sciences China Partner on CAR T-Cell and Stem Cell Manufacturing; 5.15 Grifols S.A. (GRFS); 5.15.1 Grifols U.S. Presence; 5.15.2 Grifols Revenue; 5.15.3 Grifols Acquires 24 Plasma Donation Centers in the United States; 5.15.4 Grifols Plasma Collection; 5.15.5 Grifols Bioscience Products and Services; 5.16 Hualan Biological Engineering Inc.; 5.17 Kedrion S.p.A.; 5.17.1 Kedrion Revenue; 5.18 Lake Immunogenics; 5.18.1 Lake Immunogenics Profile; 5.18.2 Operation; 5.19 Lanzhou Minhai; 5.20 Mallinckrodt; 5.21 Merck KGaA / Millipore / Sigma-Aldrich; 5.21.1 Sigma-Aldrich Cell Cytotoxicity Assay; 5.21.2 USA Origin, Sterile-Filtered, Suitable For Cell Culture, Suitable For Hybridoma; 5.21.3 Merck / BioControl Systems; 5.22 Moregate Biotech; 5.23 Newman Biotech; 5.24 Octopharma AG; 5.24.1 Octapharma R&D and Investment; 5.25 Selborne Biological Services; 5.25.1 Selborne Biological Services Animal Blood-Derived Products; 5.25.2 Selborne Biological Services Plasma; 5.26 Proliant; 5.26.1 Proliant Can Produce As Much BSA As The World Uses Each Year; 5.26.2 Proliant Closed-Loop Processing; 5.26.3 Lauridsen Group / Proliant; 5.27 Shanghai RAAS; 5.21.1 Shanghai RAAS R&D; 5.21.2 Shanghai RAAS Revenue; 5.22 Rocky Mountain Biologicals (RMBIO); 5.22.1 Rocky Mountain Biologicals Revenue; 5.28 Sanquin; 5.29 Takeda / Shire; 5.29.1 Shire Pharmaceuticals (SHPG) / Baxalta; 5.29.2 Shire Revenue; 5.29.3 Shire Hematology; 5.29.4 Shire Immunology; 5.29.5 Shire Neuroscience; 5.29.6 Shire Lysosomal Storage Diseases; 5.29.7 Shire Gastrointestinal / Endocrine; 5.29.8 Shire HAE; 5.29.9 Shire Ophthalmics; 5.29.10 Shire / Servier Oncology; 5.29.11 Takeda / Shire Financial Goals; 5.30 South Pacific Sera; 5.31 Thermo Fisher Scientific; 5.31.1 Thermo Fisher Scientific Microbiology; 5.31.2 Thermo Fisher Scientific Serum Preparation; 5.31.3 Thermo Fisher Scientific Plasma Preparation; 5.31.4 Thermo Fisher Animal Serum; 5.31.5 Thermo Fisher Scientific Quality, Performance, And Consistency Essential To Cell Culture; 5.32 Beijing Tiantan Biological Products; 5.32.1 Tiantan Bio Sales Model; 5.32.2 Tiantan Bio Management Model; 5.32.3 Tiantan Bio Profile; 5.32.4 Tiantan Bio Operation; 5.32.5 Tiantan Bio Revenue Structure; 5.32.6 Tiantan Bio R&D and Investment; 5.32.7 Tiantan Bio Development and Prospects; 5.32.8 Beijing Tiantan Biological Products; 5.32.9 Tiantan Bio Cosmetic Serum Market; 5.33 Wuhan Sanli; 5.34 Wolongsong; 5.35 ZenBio; 5.35.1 Human Serum; 5.36 Selected Chinese Blood Companies; 5.36.1 Global Animal Blood Plasma Products and Derivatives Market; 5.36.2 Global Bovine Blood Plasma Derivatives Market; 5.36.3 Blood Serum Industry Key Players.; 5.36.4 Cosmetic Serum Market; 5.36.5 Plasma Fractionation Market